bluebird bio Adjourns Annual Meeting Of Stockholders
bluebird bio, Inc. (NASDAQ: BLUE) has announced important developments related to its annual meeting of stockholders, which was partially adjourned recently. The adjournment allows the company to seek additional votes for Proposal 4, aimed at conducting a reverse stock split. This proposal is crucial for the company, especially given the current state of its stock price, which raises concerns about being de-listed from Nasdaq.
Key Details of the Annual Meeting
During the most recent meeting, several proposals were presented. Stockholders approved Proposals 1, 2, 5, 6, and 7; however, Proposal 3 did not receive the necessary support. The meeting will reconvene to solely discuss Proposal 4, which involves amending the company's Certificate of Incorporation to initiate a reverse stock split of the common stock at a ratio between 1-for-15 and 1-for-20. The determination will be made by the board of directors based on their discretion.
CEO's Insights On The Current Situation
Andrew Obenshain, CEO of bluebird bio, expressed concerns about the company's stock price in relation to its ability to achieve financial stability. In his statement, he emphasized the importance of restoring stockholder value and mentioned that the company is exploring multiple sources of capital to achieve cash flow breakeven in the near future.
Engagement with Stockholders
The management is focused on engaging with stockholders to provide necessary answers and secure votes for Proposal 4. The company recognizes that while the current votes show a favorable trend, more than 50 percent approval from total shares outstanding is essential for the reverse stock split to proceed.
Third Quarter Results Call Announcement
In addition to the annual meeting updates, bluebird bio announced a conference call dedicated to discussing third quarter 2024 results and business updates. This call is scheduled for a date that aligns with the company's planning. Time for the live call has been set for early morning ET, reflecting the company's commitment to maintaining transparency with its investors.
Accessing the Conference Call
Interested parties can access the live conference call by registering through the company’s website, which ensures confidentiality and security for participants. For those who prefer to access the live webcast, bluebird bio has made arrangements for easy access via its Investors & Media section on the company site. A replay will be available soon after, allowing stakeholders to catch up on the discussions.
About bluebird bio, Inc.
bluebird bio is a pioneer in gene therapy, dedicated to developing transformative solutions focused on severe genetic diseases. Established in 2010, the company has successfully transitioned from clinical research to achieving FDA approvals for several therapies within a short timeframe, thus setting a benchmark in the industry. Their commitment remains steadfast in bringing innovative solutions to patients and ensuring that they have the necessary support along their journey.
Focus on Patient-Centric Solutions
With the most extensive database in ex-vivo gene therapy, bluebird bio focuses on personalized therapies that address the root causes of diseases. Their programs include advanced treatments for sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy. Their ongoing efforts aim to refine analytical methods to optimize safety and efficacy in their treatments.
